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Background. Data on the relationship between homocysteine, plasminogen activator inhibitor 1, hs-CRP, ﬁbrinogen, and carotid
intima media thickness (CA-IMT) is plenty but contradicting and the majority of the studies investigated this issue in only
speciﬁc thyroidism groups. The aim of this paper was to investigate these relations in patients with subclinical and clinical hypo-
and hyperthyroidism. Methods. In this cross-sectional study, 16 patients from each thyroidism group and 20 healthy cases were
enrolled. Fibrinogen levels and plasminogen activator inhibitor 1 (PAI-1) activity were assessed. CA-IMT was determined by
gray-scale high-resolution color Doppler ultrasound. Results. Serum homocysteine levels were higher in hypothyroidic patients
compared to the control (P = 0.003). Fibrinogen levels were higher in patients with subclinical hypothyroidism compared to other
groups (P<0.05). There was no diﬀerence between groups regarding PAI-1. Whereas total cholesterol, homocysteine, and LDL
were correlated with CAIMT, hs-CRP, PAI-1, and ﬁbrinogen were not. In the clinical hypothyroidism group, the correlation of
homocysteine with CA-IMT was derived from the correlation between CA-IMT and homocysteine. Conclusions. Homocysteine
and ﬁbrinogen levels are higher in patients with clinical and subclinical hypothyroidism, respectively. Homocysteine level is
associated with CA-IMTonly in patients with clinical hypothyroidism.
1.Introduction
Thyroid diseases are among the most common endocrino-
logical disorders. Depending on the levels of thyroid hor-
mones, it may present either as normo-, hypo-, or hyperthy-
roidism. It can also be classiﬁed as subclinical (normal Thy-
roidstimulatinghormone-TSH)orclinical(abnormalTSH).
Subclinical hypothyroidism is the most common form.
Disturbancesinthyroidmetabolismaﬀectvariousorgans
such as the heart, vessels, and kidney [1–6]. With altered thy-
roid functions, changes in oxygen demand, the contractility
of the heart, cardiac output, and systemic vascular resistance
lead to a hectic environment and worsening cardiovascular
outcomes [7–9].
Cardiovascular diseases are the main causes of death
in the world. Atherosclerosis is a major contributor to
this problem. Carotid intima media thickness (CA-IMT)
measurement by Doppler USG is a validated method to
determine extent of atherosclerosis [10, 11]. Age, male
sex, smoking, diabetes, hypertension, and dyslipidemia are
among the well-known risk factors for atherosclerosis. Also,
several other risk factors such as obesity, sedentary lifestyle,
high hs-CRP, homocysteine, lipoprotein, and plasminogen
activator inhibitor 1 (PAI-1) have been linked to atheroscle-
roticcardiovasculardiseases[12].Acceleratedatherosclerosis
is well known in autoimmune rheumatic diseases compared
to other autoimmune diseases such as thyroid autoimmunity
[13, 14].
Thyroid hormones via blood vessel dilatation, produc-
tion of vasodilator molecules, inhibition of angiotensinogen
II receptor expression, and its signal transduction regulate
endothelialfunctionandvascularhomeostasisandhaveanti-
atherosclerosis eﬀects [15–18]. Regarding thyroid hormones,2 International Journal of Endocrinology
both clinical and subclinical hypothyroidism has been linked
to atherosclerosis [19, 20]. Moreover, it has been shown that
thyroid hormone replacement therapy leads to regression of
subclinical hyperthyroidism [21–24]. A major contributor
to this problem is the hyperlipidemia observed in these
patients. Data on the association between hyperthyroidism
and atherosclerosis is less clear.
Withthisbackgroundinmind,ouraimwastoinvestigate
the extent of atherosclerosis in subclinical and clinical hypo-
and hyperthyroidism along with potential roles of homo-
cysteine and PAI-1 in an otherwise healthy population.
2.MaterialsandMethods
2.1. Patients. Of the ﬁrst two patients who applied to the
endocrinology outpatient clinic with symptoms and/or signs
of thyroid dysfunction each day and met the inclusion
and exclusion criteria below were stratiﬁed into the cor-
responding thyroidism groups according to their thyroid
function results (subclinical and clinical hypothyroidism,
subclinical and clinical hyperthyroidism). Each group was
planned to consist of 16 patients. Group 1 included patients
with high TSH and normal fT3 and fT4 levels (subclinical
hypothyroidism), group 2 high TSH and low fT3 and fT4
levels (clinical hyperthyroidism), group 3 low TSH and
normal fT3 and fT4 levels (subclinical hyperthyroidism),
and group 4 low TSH and now fT3 and fT4 levels (clinical
hyperthyroidism). Also, 20 random people without any
thyroid hormone abnormality were used as control.
Inclusion criteria were to be aged between 18 and 65
years,tohavethyroidhormonedysfunctionassessedbylabo-
ratoryﬁndings,tohaveabodymassindexof20–30kg/m2,t o
havenohistoryofanykindofthyroiddysfunction,andnotto
be on thyroid hormone replacement. Exclusion criteria were
to have history of diabetes, hypertension, coronary artery
disease, and familial hypercholesterolemia, to be on lipid
lowering drugs, and to have body mass index <20kg/m2 or
>30kg/m2.
Demographical, clinical, and laboratory ﬁndings were
recorded from patients’ charts. Routine biochemical param-
eters were measured at our university’s core biochemistry
laboratory. fT3, fT4, and TSH were measured by chemilu-
minescence method by an automated analyzer (Immulite
2000, Siemens, Germany). Normal ranges for fT3 were
1.8–4.2pg/mL, for fT4 0.8–1.9ng/dL, and for TSH 0.4–
4mU/mL. Fibrinogen levels were measured nephelomet-
rically according to the manufacturer’s protocol by using
a commercially available kit on Behring BCS coagulation
analyzer (Dade Bering, Schwalbach, Germany). Plasminogen
activatorinhibitor1(PAI-1)activitywasmeasuredaccording
to the manufacturers’ protocol with indirect chromogenic
assay by using SPECTROLYSE PAI-1 ELISA kit (American
Diagnostics, USA).
The study protocol was approved by local ethics commit-
tees and informed consent was obtained from each patient.
Thestudywasperformedaccordingtotherecommendations
of the Declaration of Helsinki.
2.2. Measurement of CA-IMT. Ultrasonographic studies on
commoncarotidarterieswerecarriedoutbygray-scalehigh-
resolution color Doppler ultrasound (Prosound SSD- 3500
SV ALOKA, Zug, Switzerland) equipped with 12MHz linear
transducer. The same operator performed all procedures on
both sides of two longitudinal images of the each common
carotid artery on the morning in supine position. Average
of the two CA-IMT (proximal and distal) values from each
side was used to calculate mean CA-IMT on each side.
Intraobserver coeﬃcient of variation was 2.21%.
2.3. Statistical Analysis. A l lr e s u l t sa r er e p o r t e da sm e a n±
SD. P value less than 0.05 was considered as statistically
signiﬁcant. Comparisons between two groups were assessed
with the Student’s unpaired t-test or Mann-Whitney test,
as appropriate. Pearson’s and Spearman’s rank correlations
were used to assess correlations of ﬁbrinogen, homocysteine,
hs-CRP, and PAI-1 with left and right CA-IMT. Correlation
was analyzed both in the whole population except control
and also in the subgroups. All statistical analyses were
performed using SPSS, version 15 (Chicago, IL, USA).
3. Results
3.1. Subclinical Hypothyroidism. Mean age was 40.8 ± 11.8
years and 81.3% were female. Mean fT3, fT4, and TSH
levels were 3.02 ± 0.67pg/mL, 1.13 ± 0.24ng/mL, and
6.91 ± 1.74IU/mL. Mean homocysteine level was 12.76 ±
3.11mmol/L, hs-CRP 5.98 ± 7.84mg/L, and PAI-1 52.21 ±
31.93ng/mL. Mean CA-IMT was 0.61 ±0.11mm.
3.2. Clinical Hypothyroidism. Mean age was 38.0 ± 10.2
years and 87.5% were female. Mean fT3, fT4, and TSH
levels were 2.52 ± 0.92pg/mL, 0.76 ± 0.29ng/mL, and
29.87 ± 23.65IU/mL. Mean homocysteine level was 15.05 ±
9.87mmol/L, hs-CRP 5.41 ± 3.48mg/L, ﬁbrinogen 283.00 ±
81.16mg/dL, and PAI-1 42.78±33.65ng/mL. Mean CA-IMT
was 0.62 ±0.13mm.
3.3. Subclinical Hyperthyroidism. Mean age was 41.6 ± 16.43
years and 81.3% were female. Mean fT3, fT4, and TSH
levels were 3.46 ± 0.53pg/mL, 1.33 ± 0.18ng/mL, and
0.12 ± 0.09IU/mL. Mean homocysteine level was 11.93 ±
3.72mmol/L, hs-CRP 3.80 ± 1.72mg/L, ﬁbrinogen 275.37 ±
68.42mg/dL, and PAI-1 53.83±37.21ng/mL. Mean CA-IMT
was 0.58 ±0.17mm.
3.4.ClinicalHyperthyroidism. Meanagewas41.6±11.8y ears
and 68.8% were female. Mean fT3, fT4, and TSH levels were
6.7±3.33pg/mL, 2.90±1.70ng/mL, and 0.01±0.02IU/mL.
Mean homocysteine level was 10.23 ± 3.13mmol/L, hs-CRP
3.93±1.91mg/L,ﬁbrinogen275.37 ± 68.42mg/dL,andPAI-
15 3 .83 ±37.21ng/mL. Mean CA-IMT was 0.59 ±0.15mm.
3.5. Comparison of Groups and Correlations. As would be
expected, patients with subclinical hypothyroidism had
higher BMI compared to the control (P = 0.035). This was
more pronounced in patients with clinical hypothyroidismInternational Journal of Endocrinology 3
Table 1: Clinical and demographical characteristics of the patient population.
Subclinical
hypothyroidism
Clinical
hypothyroidism
Subclinical
hyperthyroidism
Clinical
hyperthyroidism Control
Gender (F/M) 13/31 4 /21 3 /31 1 /59 /11
Age (years) 40,8 ±11,8 38,0 ±10,2 41,6 ±16,4 41,6 ±11,8 32,8 ±5,7
BMI (kg/m2) 26,72 ±2,32
∗ 27,14 ±2,25
∗ 24,65 ±3,07 24,48 ±1,84 24,34 ±2,43
MAP (mmHg) 88,8 ±12,0 86,4 ±9,6 84,9 ±9,7 88,2 ±10,6 80,0 ±11,7
TSH (` ıIU/mL) 6,91 ±1,74
∗ 29,87 ±23,65
∗ 0,12 ±0,09
∗ 0,01 ±0,02
∗ 1,39 ±0,68
∗
sT3 (pg/mL) 3,02 ±0,67 2,52 ±0,92 3,46 ±0,53 6,7 ±3,33 3,22 ±0,97
sT4 (ng/dL) 1,13 ±0,24 0,76 ±0,29 1,33 ±0,18 2,90 ±1,70 1,4 ±0,19
T.cholestrol (mg/dL) 204 ±41
∗ 207 ±69
∗ 181 ±28 147 ±40 164 ±27
Triglyceride (mg/dL) 186 ±127 141 ±28 158 ±76 105 ±57 104 ±44
HDL (mg/dL) 41 ±84 3 ±74 1 ±64 1 ±10 42 ±11
LDL (mg/dL) 126 ±34
∗ 135 ±63
∗ 110 ±28 85 ±31 111 ±41
CA-IMT (mm) 0,61 ±0,11 0,62 ±0,13 0,58 ±0,17 0,59 ±0,15 0,53 ±0,08
∗P<0.05.
F:female;M:male;BMI:bodymassindex;MAP:meanarterialpressure;TSH:thyroidstimulatinghormone;HDL:high-densitylipoprotein;LDL:low-density
lipoprotein; CA-IMT: carotid intima media thickness.
Table 2: Homocysteine, hs-CRP, Fibrinogen, and PAI-1 levels in Thyroidism groups.
SCHypo CHypo SCHyper CHyper Control
Homocysteine (mmol/L) 12,76 ±3,11 15,05 ±9,87 11,93 ±3,72 10,23 ±3,13 8,41 ±3,86
Hs-CRP (mg/L) 5,98 ±7,84 5,41 ±3,48
∗ 3,80 ±1,72 3,93 ±1,91 3,48 ±0,64
Fibrinogen (mg/dL) 327,56 ±100,84
∗ 283,00 ±81,16 275,37 ±68,42 273,56 ±76,08 271,50 ±52,47
PAI-1 (ng/mL) 52,21 ±31,93 42,78 ±33,65 53,83 ±37,21 64,19 ±34,38 54,06 ±33,78
∗P<0.05.
PAI-1: plasminogen activator inhibitor-1; SCHypo: subclinical hypothyroidism; CHypo: clinical hypothyroidism; SCHyper: subclinical hyperthyroidism;
CHyper: clinical hyperthyroidism.
(P = 0.008).Asimilartrendwastruefortotalcholesteroland
LDL levels. Comparison of the clinical and demographical
parameters of the groups is shown in Table 1.
Serum homocysteine levels were signiﬁcantly higher in
hypothyroidic patients compared to the control (P = 0.003).
There was no diﬀerence between hypo- and hyperthyroidic
patients. Fibrinogen levels were higher in patients with
subclinical hypothyroidism compared to other groups (P<
0.05). There was no diﬀerence between groups regard-
ing PAI-1. Comparison of the clinical and demographical
parameters of the groups is presented in Table 2.
Whereas total cholesterol, LDL, and homocysteine were
correlatedwithCA-IMT,hs-CRP,PAI-1,andﬁbrinogenwere
not (Figure 1). The correlation of homocysteine with CA-
IMT was derived from the strong correlation in the clinical
hypothyroidism group (Figure 1).
4. Discussion
In this study, we provide, for the ﬁrst time, data on the
association between several novel surrogate cardiovascular
markers (hs-CRP, ﬁbrinogen, homocysteine, and PAI-1)
and CA-IMT in patients with clinical/subclinical hypo- and
hyperthyroidism. Only homocysteine level was associated
with CA-IMT and this was derived from the strong associ-
ation between homocysteine and CA-IMT in patients with
clinical hypothyroidism.
Data on PAI-1 in thyroid diseases is controversial. Erem
et al. reported higher levels patients with hypothyroidism
compared to the controls [25, 26]. This was indeed linked to
higher risk of peripheral thrombosis [25]. Contrary, another
studyfoundlowerlevelsinpatientswithsubclinicalhypothy-
roidism [27]. In other studies, there was no diﬀerence in
PAI-1 levels in patients with subclinical hypothyroidism
compared to the control [28, 29]. In hyperthyroidic patients,
higher levels in patients with hyperthyroidism were reported
[30, 31]. Our results conﬁrm no diﬀerence between hypo-
and hyperthyroidism groups and also with control. Also,
we report that in these patients PAI-1 levels are not related
to CA-IMT, a marker of atherosclerosis. We also did not
ﬁnd any association between BMI and PAI-1 levels, which is
proposed as a production site for PAI-1 in any of the groups
[32].
Hyperhomocysteinemia is proposed as a contributor
to atherosclerosis by stimulating oxidation of LDL and
causing endothelial dysfunction [33–35]. Both hypothy-
roidism and hyperthyroidism are associated with alterations
in homocysteine levels [36–38]. It is suggested that levels
are increased in hypothyroidic patients and are decreased
in hyperthyroidic patients [39]. Hypothyroidism has been
proposed to decrease hepatic levels of enzymes involved
in homocysteine metabolism. Also alteration of LDL in
hypothyroidism makes it plausible. In the New Mexico Elder4 International Journal of Endocrinology
Homocysteine Hs-CRP Fibrinogen PAI-I
0.049 0.092 0.076 CA-IMT
SCHypo CHypo SCHyper CHyper Control
0.338 0.375 −0.132 0.569∗ −0.376
0.342∗
∗P<0.01
Figure 1: Correlations between homocysteine, hs-CRP, ﬁbrinogen, PAI-1, and CA-IMT and correlations of homocysteine and CA-IMT
between thyroidism groups. PAI-I: plasminogen activator inhibitor-1; CA-IMT: carotid intima media thickness; SCHypo: subclinical
hypothyroidism; CHypo: clinical hypothyrodism; SCHypo: subcilinical hyperthyroidism; CHyper: clinical hyperthyroidism.
Health survey, no diﬀerence in patients with subclinical
hypothyroidism (n = 112) compared to patients with
TSH ≤ 4.6mcu/mL (643) was observed [40]. Our study
conﬁrms the ﬁnding that levels are higher in clinically
hypothyroidicpatientscomparedtocontrolandnotdiﬀerent
fromthecontrolinpatientswithsubclinicalhypothyroidism.
In line with the previous literature, levels are lower in
hyperthyroidic patients compared to hypothyroidic patients
but are not statistically diﬀerent than the control.
The association between homocysteine levels and CA-
IMT is not clear [41–43]. Data on this topic is almost
nonexistent in patients with thyroid disease. Our results
show a positive correlation between homocysteine levels and
CA-IMT derived from the strong correlation between these 2
parameters in patients with clinical hypothyroidism.
Several studies have reported a positive association
between CRP levels and cardiovascular events and
atherosclerosis [44–47]. However causality of CRP on
atherosclerosis remains unclear. It is suggested that CRP
may be a reﬂection of the inﬂammation caused by smoking,
obesity, metabolic syndrome, and other classical cardiovas-
cular risk factors [48, 49]. Various studies have reported
contradicting results on association between CRP levels and
severity and progression of atherosclerosis [50–53].
In patients with hypothyroidism data on the level of CRP
is contradictory [54–58]. In a study by Christ-Crain et al.,
despite no association between thyroid hormone levels and
CRP, levels were found higher in hypothyroidic patients, but
thyroid hormone replacement did not have any eﬀect on
CRP levels in patients with subclinical hypothyroidism [59].
A similar ﬁnding was observed in the study by Lee et al. In
our study, levels were higher in patients with subclinical and
clinical hypothyroidism compared to other groups, but yet
not statistically signiﬁcant. Also, no relation with CA-IMT
was present. Possible explanation for these results may be the
diﬀerencesinthestudypopulation,aswellasthesamplesize.
Our results also conﬁrm the previous data that CRP levels
are not diﬀerent from controls in hyperthyroidic patients
[60, 61].
The strongest side of our study is comparison between
thyroidism subgroups along with a comparison with a con-
trol. The major limitation of our study is its cross-sectional
nature and measurement at one time-point. Despite most of
thestudiesintheliteraturehaveenrolledlessthan30patients
in comparison studies, the number of patients in each group
inourstudymaystillbeconsideredrelativelysmall.Afurther
study enrolling higher number of patients and analyzing the
value of these parameters in a time-dependent manner may
yield more data on this issue.
As a conclusion, our results show that homocysteine
and ﬁbrinogen levels are higher in patients with clinical
and subclinical hypothyroidism, respectively. Homocysteine
level was associated with CA-IMT in patients with thy-
roidism, and this was derived from the strong association
between homocysteine and CA-IMT in patients with clinical
hypothyroidism. Determination of homocysteine in clinical
hypothyroidic patients may provide information on the
cardiovascularburden.Also,therapytoreducehomocysteine
levels may be an important approach in these patients to
decrease the cardiovascular burden.
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